Biohaven Pharmaceutical Holding Co. Ltd. was the third company to bring a new drug for acute treatment of migraine attacks to the US market after two decades with no new on-demand therapies, but based on positive results from the latest Phase III clinical trial for Nurtec (rimegepant) it could be the first firm to win US Food and Drug Administration approval for an oral preventive therapy and the first with a dual purpose migraine medicine on the market.
The company plans to submit a supplemental new drug application to the US FDA by mid-year after reporting positive Phase...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
